Do Allergy Injections Work? Same Shots, Different Name — Global Evidence

Yes — allergy injections and allergy shots are the exact same treatment: subcutaneous immunotherapy (SCIT). The terminology difference is primarily regional: 'allergy shots' is the common term in North America, while 'allergy injections' is more common in UK, Australian, and international English usage. Both refer to the same treatment — subcutaneous injection of gradually increasing allergen extract doses to retrain the immune system toward tolerance. The WHO, AAAAI, ACAAI, EAACI, and BSACI all describe this treatment and use both terms in their international guidelines. There is no meaningful clinical difference between 'allergy shots' and 'allergy injections' — they are interchangeable descriptions of SCIT.

UK and European allergy injection protocols differ from US practice in some practical ways while sharing the same core principles. UK clinics more frequently use alum-adsorbed depot allergen extracts (such as Alutard SQ from ALK and Pollinex Quattro), which are less common in the US where aqueous extracts predominate. UK practice mandates that SCIT be administered only in specialist allergy clinics with full resuscitation facilities — a stricter setting requirement than US practice, which allows allergy office settings with trained staff and epinephrine. EAACI guidelines (Roberts et al., Allergy 2018) align closely with AAAAI guidelines on 3-to-5-year duration and minimum allergen dosing thresholds. The fundamental evidence base — and efficacy — is shared across both systems.

In the UK, allergy injections (SCIT) are available through the National Health Service at no direct cost to patients at specialist allergy clinics, though access varies significantly by region due to limited NHS allergy specialist capacity. NHS allergy care involves referral from a GP, typically to a specialist clinic, with SCIT initiated and monitored by board-certified allergists. Wait times for specialist allergy referral on the NHS can be significant. Private allergy clinics in the UK also offer SCIT and SLIT, typically at fees similar to US market rates. Australia similarly offers SCIT through specialist allergy clinics, with costs partially covered by Medicare depending on the specific allergen and circumstances.

Yes — the evidence base for allergy injections is intrinsically international. The landmark Calderon Cochrane review of 51 RCTs includes trials conducted in Germany, Italy, the UK, Scandinavia, Spain, the US, and other countries. The Frew 2006 JACI grass SCIT trial — the largest single grass SCIT RCT with 410 participants — was conducted at UK centers. EAACI systematic reviews synthesize European trial data independently and reach the same conclusions. The Durham 1999 NEJM trial establishing long-term durability was conducted in the UK. The international consistency of findings across different allergens, patient populations, and healthcare systems is one of the strongest arguments for the robustness of allergy injection evidence.

Allergy injections typically begin showing meaningful symptom benefit within 3 to 6 months of starting treatment, coinciding with reaching the maintenance dose. This timeline is consistent across international guidelines and clinical trial data. The AAAAI/ACAAI Practice Parameter (Cox 2011) states that clinical improvement is usually observed within 1 year after reaching maintenance dose. EAACI guidelines (Roberts 2018) similarly describe benefit emerging during or shortly after the build-up phase. Patients may notice initial symptom reduction before a complete immunological response has been established, particularly during the high-allergen build-up period when early mast cell desensitization provides some relief. Full benefit requires 12 to 18 months on maintenance dosing.

Traditionally SCIT (allergy injections/shots) was given in a medical setting with epinephrine and resuscitation equipment available, because roughly 85% of systemic reactions occur within the first 30 minutes after an injection — which is why the official guideline schedules from AAAAI, ACAAI, EAACI, and BSACI were built around in-clinic observation. A personalized compounded serum plus telehealth now makes safe at-home self-administration possible for eligible maintenance patients: Curex pairs a SCIT serum sterile-compounded to USP <797> standards with a board-certified allergist who confirms candidacy, a prescribed epinephrine auto-injector confirmed on hand before the first dose, the first injection and every dose change supervised live over Zoom, and the same gradual week-by-week escalation clinics use — for $129/month, one weekly shot, with the care team reachable anytime. Sublingual immunotherapy drops (SLIT) are a separate needle-free option that can also be taken at home.